Maintenance of Remission with Partial Enteral Nutrition Therapy in Pediatric Crohn’s Disease: A Retrospective Study

Table 2

Remission rates and concomitant medication.

Covariate	PEN group	Control group	value
Time between diagnosis and EEN initiation (mo), median (range)	2.0 (0–112)
Route of EN administration, (%)
Oral	37/42 (88)
Nasogastric	4/42 (10)
PEG	1/42 (2)
Follow-up time (mo), median 25–75%	40 25.5–79	63 52–87
Length of remission (mo), median (range)	6.0 (0–36)	6.0 (range: 0–45)
Concomitant medication, (%)
Corticosteroids	26 (62)	35 (78)
Thiopurines	35 (83)	30 (67)
Anti-TNF agents	14 (33)	10 (22)
Methotrexate	7 (17)	2 (4)
Antibiotics	19 (45)	19 (42)
Time on PEN without concomitant medication (mo), median (range)	0 (0–36)
0	23/43 (55%)
1–6	13/42 (31%)
7–12	2/42 (5%)
13+	4/42 (9%)
Length of remission with PEN alone, without concomitant medication (mo), median (range)	0 (0–16)
0	25/42 (60%)
1–6	14/42 (33%)
7–12	2/42 (5%)
13+	1/42 (2%)

mo, months; EEN, exclusive enteral nutrition; PEN, partial enteral nutrition; EN, enteral nutrition; PEG, Percutaneous endoscopic gastrostomy; TNF, tumor necrosis factor. Calculated with Chi-square or Fisher’s exact test for categorical data and independent samples -test for continuous variables. Calculated with Mann–Whitney tests.